Condition: Advanced Solid Tumor · Cholangiocarcinoma · HER2-negative Breast Cancer · Sponsor: TransThera Sciences (Nanjing), Inc.
This is a Phase Ib/II, multicenter, open-label study to evaluate the safety and preliminary efficacy of TT-00420 tablet, as monotherapy or in combination regimens, in patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | — |
| The University of Chicago | Chicago, Illinois, United States | — |
| Rutgers Cancer Institute | New Brunswick, New Jersey, United States | — |
| Gabrail Cancer Center Research | Canton, Ohio, United States | — |
| UT Southwestern Medical Center | Dallas, Texas, United States | — |
| MD Anderson Cancer Center | Houston, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04742959